Table 2.
Clinical characteristics of the patients with advanced gastric cancer in the two groups
| Characteristic | Total (n=28) | Control (n=15) | Experimental (n=13) | χ2 | P-value |
|---|---|---|---|---|---|
| Sex | 0.346 | 0.686 | |||
| Male | 20 | 10 | 10 | ||
| Female | 8 | 5 | 3 | ||
| Age (years) | 0.185 | 0.718 | |||
| <60 | 12 | 7 | 5 | ||
| >60 | 16 | 8 | 8 | ||
| Tumor site | 0.428 | 0.689 | |||
| Gastric cardia | 19 | 11 | 8 | ||
| Gastric body | 9 | 4 | 5 | ||
| Histologic differentiation | 0.597 | 0.476 | |||
| Moderately differentiated | 10 | 7 | 8 | ||
| Poorly differentiated | 18 | 8 | 5 | ||
| Tumor stage | 0.712 | 0.460 | |||
| III | 19 | 8 | 9 | ||
| IV | 9 | 7 | 4 | ||
| Chemotherapy regimen | 0.038 | 1.000 | |||
| FOLFOX4 | 22 | 12 | 10 | ||
| DCF | 6 | 3 | 3 |
Abbreviations: DCF, docetaxel, cisplatin, 5-florouracil; FOLFOX4, folinic acid, fluorouracil, oxaliplatin.